Study Finds Meningitis Vaccine Shows Promise
- By BSTQ Staff
According to a new study, a meningitis vaccine tested in two African countries has shown promise in the fight against the disease, eliciting immune responses against five main strains. The Phase III randomized trials were conducted on 1,800 people in the West African nations of Mali and The Gambia.
The under-trial NmCV-5 vaccine, developed by the health organization PATH and India’s Serum Institute, was tested and compared with the World Health Organization-approved and licensed MenACWY-D vaccine in participants in three age groups between two and 29 years old. Results showed immune response from one dose of the NmCV-5 was notably higher than the licensed vaccine. No major safety concerns were found during the trial.
The vaccine will provide protection against the types of meningitis bacteria that cause most of the devastating epidemics in Africa.
References
- New Vaccine Trials Show Promise in Fight Against Meningitis. Al Jazeera, May 25, 2023. Accessed at www.aljazeera.com/news/2023/5/25/new-vaccine-trials-show-promise-in-fight-against-meningitis.
